Symptomatic profiles of patients with polycythemia vera: implications of inadequately controlled disease
Purpose: Polycythemia vera (PV) is a myeloproliferative neoplasm (MPN) associated with disabling symptoms and a heightened risk of life-threatening complications. Recent studies have demonstrated the effectiveness of JAK inhibitor therapy in patients with PV patients who have a history of prior hydr...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
January 10, 2016
|
| In: |
Journal of clinical oncology
Year: 2016, Jahrgang: 34, Heft: 2, Pages: 151-159 |
| ISSN: | 1527-7755 |
| DOI: | 10.1200/JCO.2015.62.9337 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1200/JCO.2015.62.9337 Verlag, Volltext: http://ascopubs.org.ezproxy.medma.uni-heidelberg.de/doi/10.1200/JCO.2015.62.9337 
|
| Verfasserangaben: | Holly Geyer, Robyn Scherber, Heidi Kosiorek, Amylou C. Dueck, Jean-Jacques Kiladjian, Zhijian Xiao, Stefanie Slot, Sonja Zweegman, Federico Sackmann, Ana Kerguelen Fuentes, Dolores Hernández-Maraver, Konstanze Döhner, Claire N. Harrison, Deepti Radia, Pablo Muxi, Carlos Besses, Francisco Cervantes, Peter L. Johansson, Bjorn Andreasson, Alessandro Rambaldi, Tiziano Barbui, Karin Bonatz, Andreas Reiter, Francoise Boyer, Gabriel Etienne, Jean-Christophe Ianotto, Dana Ranta, Lydia Roy, Jean-Yves Cahn, Norman Maldonado, Giovanni Barosi, Maria L. Ferrari, Robert Peter Gale, Gunnar Birgegard, Zefeng Xu, Yue Zhang, Xiujuan Sun, Junqing Xu, Peihong Zhang, Peter A.W. te Boekhorst, Suzan Commandeur, Harry Schouten, Heike L. Pahl, Martin Griesshammer, Frank Stegelmann, Thomas Lehmann, Zhenya Senyak, Alessandro M. Vannucchi, Francesco Passamonti, Jan Samuelsson, and Ruben A. Mesa |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1586132199 | ||
| 003 | DE-627 | ||
| 005 | 20230427034200.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190111s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/JCO.2015.62.9337 |2 doi | |
| 035 | |a (DE-627)1586132199 | ||
| 035 | |a (DE-576)516132199 | ||
| 035 | |a (DE-599)BSZ516132199 | ||
| 035 | |a (OCoLC)1341033239 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Geyer, Holly L. |e VerfasserIn |0 (DE-588)1160259666 |0 (DE-627)1023409046 |0 (DE-576)505287110 |4 aut | |
| 245 | 1 | 0 | |a Symptomatic profiles of patients with polycythemia vera |b implications of inadequately controlled disease |c Holly Geyer, Robyn Scherber, Heidi Kosiorek, Amylou C. Dueck, Jean-Jacques Kiladjian, Zhijian Xiao, Stefanie Slot, Sonja Zweegman, Federico Sackmann, Ana Kerguelen Fuentes, Dolores Hernández-Maraver, Konstanze Döhner, Claire N. Harrison, Deepti Radia, Pablo Muxi, Carlos Besses, Francisco Cervantes, Peter L. Johansson, Bjorn Andreasson, Alessandro Rambaldi, Tiziano Barbui, Karin Bonatz, Andreas Reiter, Francoise Boyer, Gabriel Etienne, Jean-Christophe Ianotto, Dana Ranta, Lydia Roy, Jean-Yves Cahn, Norman Maldonado, Giovanni Barosi, Maria L. Ferrari, Robert Peter Gale, Gunnar Birgegard, Zefeng Xu, Yue Zhang, Xiujuan Sun, Junqing Xu, Peihong Zhang, Peter A.W. te Boekhorst, Suzan Commandeur, Harry Schouten, Heike L. Pahl, Martin Griesshammer, Frank Stegelmann, Thomas Lehmann, Zhenya Senyak, Alessandro M. Vannucchi, Francesco Passamonti, Jan Samuelsson, and Ruben A. Mesa |
| 264 | 1 | |c January 10, 2016 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 11.01.2019 | ||
| 520 | |a Purpose: Polycythemia vera (PV) is a myeloproliferative neoplasm (MPN) associated with disabling symptoms and a heightened risk of life-threatening complications. Recent studies have demonstrated the effectiveness of JAK inhibitor therapy in patients with PV patients who have a history of prior hydroxyurea (HU) use (including resistance or intolerance), phlebotomy requirements, and palpable splenomegaly. We aimed to determine how these features contribute alone and in aggregate to the PV symptom burden. Patients and Methods: Through prospective evaluation of 1,334 patients with PV who had characterized symptom burden, we assessed patient demographics, laboratory data, and the presence of splenomegaly by disease feature (ie, known HU use, known phlebotomy requirements, splenomegaly). Results: The presence of each feature in itself is associated with a moderately high symptom burden (MPN symptom assessment form [SAF] total symptom score [TSS] range, 27.7 to 29.2) that persists independent of PV risk category. In addition, symptoms incrementally increase in severity with the addition of other features. Patients with PV who had all three features (PV-HUPS) faced the highest total score (MPN-SAF TSS, 32.5) but had similar individual symptom scores to patients with known HU use (PV-HU), known phlebotomy (PV-P), and splenomegaly (PV-S). Conclusion: The results of this study suggest that patients with PV who have any one of the features in question (known HU use, known phlebotomy, or splenomegaly) have significant PV-associated symptoms. Furthermore, it demonstrates that many PV symptoms remain severe independent of the number of features present. | ||
| 700 | 1 | |a Bonatz, Karin |e VerfasserIn |0 (DE-588)116025995X |0 (DE-627)1023409569 |0 (DE-576)167430327 |4 aut | |
| 700 | 1 | |a Reiter, Andreas |d 1964- |e VerfasserIn |0 (DE-588)172629551 |0 (DE-627)697563766 |0 (DE-576)133488594 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical oncology |d Alexandria, Va. : American Society of Clinical Oncology, 1983 |g 34(2016), 2, Seite 151-159 |h Online-Ressource |w (DE-627)313116962 |w (DE-600)2005181-5 |w (DE-576)090887018 |x 1527-7755 |7 nnas |a Symptomatic profiles of patients with polycythemia vera implications of inadequately controlled disease |
| 773 | 1 | 8 | |g volume:34 |g year:2016 |g number:2 |g pages:151-159 |g extent:9 |a Symptomatic profiles of patients with polycythemia vera implications of inadequately controlled disease |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1200/JCO.2015.62.9337 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://ascopubs.org.ezproxy.medma.uni-heidelberg.de/doi/10.1200/JCO.2015.62.9337 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190111 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 172629551 |a Reiter, Andreas |m 172629551:Reiter, Andreas |d 60000 |d 61200 |e 60000PR172629551 |e 61200PR172629551 |k 0/60000/ |k 1/60000/61200/ |p 23 | ||
| 998 | |g 116025995X |a Bonatz, Karin |m 116025995X:Bonatz, Karin |d 60000 |d 61200 |e 60000PB116025995X |e 61200PB116025995X |k 0/60000/ |k 1/60000/61200/ |p 22 | ||
| 999 | |a KXP-PPN1586132199 |e 3039642685 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title":"Symptomatic profiles of patients with polycythemia vera","subtitle":"implications of inadequately controlled disease","title_sort":"Symptomatic profiles of patients with polycythemia vera"}],"language":["eng"],"physDesc":[{"extent":"9 S."}],"name":{"displayForm":["Holly Geyer, Robyn Scherber, Heidi Kosiorek, Amylou C. Dueck, Jean-Jacques Kiladjian, Zhijian Xiao, Stefanie Slot, Sonja Zweegman, Federico Sackmann, Ana Kerguelen Fuentes, Dolores Hernández-Maraver, Konstanze Döhner, Claire N. Harrison, Deepti Radia, Pablo Muxi, Carlos Besses, Francisco Cervantes, Peter L. Johansson, Bjorn Andreasson, Alessandro Rambaldi, Tiziano Barbui, Karin Bonatz, Andreas Reiter, Francoise Boyer, Gabriel Etienne, Jean-Christophe Ianotto, Dana Ranta, Lydia Roy, Jean-Yves Cahn, Norman Maldonado, Giovanni Barosi, Maria L. Ferrari, Robert Peter Gale, Gunnar Birgegard, Zefeng Xu, Yue Zhang, Xiujuan Sun, Junqing Xu, Peihong Zhang, Peter A.W. te Boekhorst, Suzan Commandeur, Harry Schouten, Heike L. Pahl, Martin Griesshammer, Frank Stegelmann, Thomas Lehmann, Zhenya Senyak, Alessandro M. Vannucchi, Francesco Passamonti, Jan Samuelsson, and Ruben A. Mesa"]},"note":["Gesehen am 11.01.2019"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"person":[{"family":"Geyer","display":"Geyer, Holly L.","role":"aut","given":"Holly L."},{"display":"Bonatz, Karin","family":"Bonatz","role":"aut","given":"Karin"},{"given":"Andreas","role":"aut","display":"Reiter, Andreas","family":"Reiter"}],"relHost":[{"language":["eng"],"title":[{"title_sort":"Journal of clinical oncology","subtitle":"JCO : an American Society of Clinical Oncology journal","title":"Journal of clinical oncology"}],"physDesc":[{"extent":"Online-Ressource"}],"note":["Fortsetzung der Druck-Ausgabe","Gesehen am 22.05.23"],"origin":[{"dateIssuedKey":"1983","publisherPlace":"Alexandria, Va. ; Baltimore, Md. [u.a.]","dateIssuedDisp":"1983-","publisher":"American Society of Clinical Oncology ; Lippincott Williams & Wilkins"}],"id":{"issn":["1527-7755"],"eki":["313116962"],"zdb":["2005181-5"]},"pubHistory":["1.1983 -"],"corporate":[{"display":"American Society of Clinical Oncology","role":"isb"}],"disp":"Symptomatic profiles of patients with polycythemia vera implications of inadequately controlled diseaseJournal of clinical oncology","part":{"year":"2016","extent":"9","issue":"2","text":"34(2016), 2, Seite 151-159","pages":"151-159","volume":"34"},"recId":"313116962","titleAlt":[{"title":"official journal of the American Society of Clinical Oncology"},{"title":"JCO"},{"title":"Journal of clinical oncology legacy archive (ASCO)"}],"type":{"bibl":"periodical","media":"Online-Ressource"}}],"recId":"1586132199","id":{"doi":["10.1200/JCO.2015.62.9337"],"eki":["1586132199"]},"origin":[{"dateIssuedDisp":"January 10, 2016","dateIssuedKey":"2016"}]} | ||
| SRT | |a GEYERHOLLYSYMPTOMATI1020 | ||